{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.4","upperLimit":"45.4","value":"33.8"},{"groupId":"OG001","lowerLimit":"29.3","upperLimit":"61.5","value":"45.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Confirmed ORR is defined as the proportion of participants in each cohort who have a confirmed CR or confirmed PR, as assessed by ICR per RECIST 1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Final Analysis with DCO on 27Nov2024","id":"OG001","title":"NSCLC Cohort"}],"paramType":"NUMBER","populationDescription":"RES: Enrolled participants who received at least one dose of study intervention and had measurable disease at baseline by ICR.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.","title":"Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}